Ironwood Pharma (IRWD) Misses Q2 EPS by 12c; Reiterates Outlook
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/20/2026
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Oil slides after China asks Iran to limit Houthi attacks on Saudi oil facilities
- Warren Buffett transitions to Berkshire’s chairman emeritus
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- S&P 500, Nasdaq advance, turning the page on a tumultuous week
- Anthropic and Accenture partner on embedded AI safety evaluation
- Wells Fargo cuts Netflix rating on engagement risk, weak slate
- Wells Fargo Downgrades Netflix (NFLX) to Underweight on Engagement Risks, 'We see tougher choices ahead'
- Is the S&P 500 in an "earnings bubble"? Goldman weighs in
Ironwood Pharmaceuticals Reports Second Quarter 2022 Results; Maintains Full Year Guidance Due to Continued Strength of LINZESS® Prescription Demand
August 4, 2022 7:00 AM EDTLINZESS (Iinaclotide) EUTRx prescription demand growth in Q2 2022 increased 9% year-over-year
GAAP net income of $37 million and adjusted EBITDA of $56 million; ended Q2 2022 with $504 million in cash and cash equivalents
Completes Board of Directors authorized share repurchase program; repays remaining principal amount of the 2022 Convertible Notes in cash
Reiterates 2022 guidance of U.S. LINZESS net sales growth of low single digits %, total Ironwood revenue of $420 to $430 million and adjusted EBITDA of >$250 million
BOSTON--(BUSINESS... More
